OpenURL Connection Search

Select item for more details and to access through your institution.

S2207: RANDOMIZED PHASE II STUDY OF THE ADDITION OF TARGETED AGENTS TO TAFASITAMAB‐LENALIDOMIDE IN TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LBCL.
Published in:
Hematological Oncology, 2023, v. 41, p. 842, doi. 10.1002/hon.3166_OT22
By:
- Amengual, J. E.;
- Reagan, P.;
- Li, H.;
- Saeed, H.;
- Vaidya, R.;
- Unger, J. M.;
- Danilov, A.;
- LeBlanc, M.;
- Friedberg, J. W.;
- Smith, S. M.
Publication type:
Article
ETCTN P10500: PHASE 1/EXPANSION STUDY OF TAZEMETOSTAT PLUS BELINOSTAT FOR THE TREATMENT OF RELAPSED OR REFRACTORY LYMPHOMA.
Published in:
Hematological Oncology, 2023, v. 41, p. 833, doi. 10.1002/hon.3166_OT14
By:
- Amengual, J. E.;
- Shyr, Y.;
- Durecki, D.;
- Beumer, J. H.;
- Mansukhani, M. M.;
- Williams, M.;
- Kelleher, N.;
- Cherng, H.;
- Pro, B.;
- Schwartz, G. K.;
- LoRusso, P.;
- Piekarz, R.
Publication type:
Article
Outcomes of contemporary novel agent incorporation in relapsed/refractory PTCL.
Published in:
Hematological Oncology, 2023, v. 41, p. 511, doi. 10.1002/hon.3164_377
By:
- Tolu, S. S.;
- Seshadri, M. R.;
- Chen, Z.;
- Orlando, E.;
- Grenet, J.;
- Toor, R.;
- Sanjurjo, A.;
- Phillips, A.;
- Shore, T.;
- Martin, P.;
- Leonard, J. P.;
- Pro, B.;
- Amengual, J. E.;
- Ruan, J.
Publication type:
Article
SURVIVAL FOLLOWING FIRST RELAPSE IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.60_2880
By:
- Karmali, R.;
- Donovan, A.;
- Wagner‐Johntson, N.;
- Messmer, M.;
- Mehta, A.;
- Anderson, J. K.;
- Reddy, N.;
- Kovach, A. E.;
- Landsburg, D. J.;
- Glenn, M.;
- Inwards, D. J.;
- Ristow, K.;
- Lansigan, F.;
- Kaplan, J. B.;
- Caimi, P. B.;
- Rajguru, S.;
- Evens, A.;
- Klein, A.;
- Umyarova, E.;
- Amengual, J. E.
Publication type:
Article

Found: 4

S2207: RANDOMIZED PHASE II STUDY OF THE ADDITION OF TARGETED AGENTS TO TAFASITAMAB‐LENALIDOMIDE IN TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LBCL.

ETCTN P10500: PHASE 1/EXPANSION STUDY OF TAZEMETOSTAT PLUS BELINOSTAT FOR THE TREATMENT OF RELAPSED OR REFRACTORY LYMPHOMA.

Outcomes of contemporary novel agent incorporation in relapsed/refractory PTCL.

SURVIVAL FOLLOWING FIRST RELAPSE IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA.